HALEON PLC

Haleon PLC faces a modest price‑target revision from Berenberg and KPMG, keeping a neutral outlook while urging investors and clinicians to watch upcoming earnings and product updates closely.

Haleon PLC’s strategy to beat regulatory tightening, capitalize on the ageing UK market, and launch a digital wellness platform could boost its 2024 earnings and secure a lead in consumer‑healthcare OTC products.

Haleon PLC’s steady rise in a booming cardiovascular‑health supplement market: evidence‑based trials, regulatory alignment, and investor upside.

Explore Haleon PLC’s latest shareholding shift, new director role, and PDMR policy—why it matters for investors, digital‑health growth, and regulatory compliance.

Haleon names Jon Workman President of European Operations, boosting leadership to strengthen market share, optimize distribution, and accelerate OTC and nutraceutical growth.

Deutsche Bank downgrades Haleon PLC to sell, citing slower earnings and rising costs; other analysts stay neutral, highlighting resilience and potential for strategic moves.

Haleon PLC shows solid financials and steady growth, leveraging strong OTC brands, low payer exposure, and digital strategy to stay resilient amid market volatility.

Haleon PLC gains investor interest after Goldman Sachs upgrade, showing steady sales in Pakistan and a growing European pain‑management portfolio, while advancing digital health and supply‑chain resilience for long‑term growth.

Haleon PLC’s OTC portfolio shows price stability amid scientific R&D; investors watch clinical trials and regulatory updates on oral‑care, vitamins, and pain relief.

Haleon PLC remains steady amid market volatility, leveraging a strong core portfolio—oral health, vitamins, cold & flu, pain‑relief—while quietly expanding globally and maintaining healthy margins to navigate inflation and supply‑chain pressures.